TongaTuberculosis profile
Population  2018 <1 million
Estimates of TB burdenº, 2018 Number (thousands) Rate
(per 100 000 population)
Total TB incidence 0.01 (<0.01–0.012) 10 (8.6–12)
HIV-positive TB incidence 0 (0–<0.01) 0 (0–1.7)
MDR/RR-TB incidenceºº 0 (0–0) 0.02 (0.01–0.04)
HIV-negative TB mortality 0 (0–<0.01) 0.82 (0.48–1.3)
HIV-positive TB mortality 0 (0–0) 0 (0–0.26)
Estimated proportion of TB cases with MDR/RR-TB, 2018
New cases 0% (0–41)
Previously treated cases 11% (6.1–17)
TB case notifications, 2018  
Total new and relapse 9
          - % tested with rapid diagnostics at time of diagnosis 89%
          - % with known HIV status 100%
          - % pulmonary 89%
          - % bacteriologically confirmedººº 88%
          - % children aged 0-14 years 0%
          - % women 33%
          - % men 67%
Total cases notified 9
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2018 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2018 8% (5–13)
TB/HIV care in new and relapse TB patients, 2018 Number (%)
Patients with known HIV status who are HIV-positive 0 0%
          - on antiretroviral therapy 0  
Drug-resistant TB care, 2018
% of bacteriologically confirmed TB cases tested for rifampicin resistance ººº
          - New cases 100%
          - Previously treated cases  
Laboratory-confirmed cases* MDR/RR-TB: 0, XDR-TB: 0
Patients started on treatment* ** MDR/RR-TB: 0, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2017 82% 11
Previously treated cases, excluding relapse, registered in 2017   0
HIV-positive TB cases registered in 2017   0
MDR/RR-TB cases started on second-line treatment in 2016   0
XDR-TB cases started on second-line treatment in 2016   0
TB preventive treatment, 2018  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2019  
National TB budget (US$ millions) <1
º Ranges represent uncertainty intervals
ºº MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Incidence graph
   Total TB incidence
   New and relapse TB cases notified
   HIV-positive TB incidence

(Rate per 100 000 population per year)
Mortality graph
   HIV-negative TB mortality

Notified cases by age group and sex, 2018
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2020-01-21 Data: www.who.int/tb/data